Terns Pharmaceuticals, Inc. Free Cash Flow Margin

Free Cash Flow Margin of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2021 was -4216.7% (a -Infinity% decrease from previous year)
  • Annual Free Cash Flow Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Free Cash Flow Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin decreased by NaN% year-over-year
Trailing Free Cash Flow Margin for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of Terns Pharmaceuticals, Inc.

Most recent Free Cash Flow Marginof TERN including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -4216.7%
2020 0.0%
2019 0.0%
2018 0.0%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.